Evidence map›Paper›PMID 26397159›Full record

Trial reportInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2016

Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

Ramez N Eskander, Shamshad Ali, Thanh Dellinger, Heather A Lankes, Leslie M Randall, Nilsa C Ramirez, Bradley J Monk, Joan L Walker, Eric Eisenhauer, Bang H Hoang

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Ramez N Eskander*Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, Medical Center, Orange, CA; †Gynecologic Oncology Group, Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; ‡Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, City of Hope Comprehensive Cancer Center, Duarte, CA; §The Research Institute at Nationwide Children's Hospital, Columbus, OH; ∥Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arizona Cancer Center, Creighton University School of Medicine, St Joseph's Hospital and Medical Center, Phoenix, AZ; ¶Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK; #Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine, Cincinnati, OH; and **Department of Orthopedic Surgery, University of California, Irvine, Orange, CA.
Shamshad Ali
Thanh Dellinger
Heather A Lankes
Leslie M Randall
Nilsa C Ramirez
Bradley J Monk
Joan L Walker
Eric Eisenhauer
Bang H Hoang
City of Hope · USCreighton University · USGynecologic Oncology Group · USNationwide Children's Hospital · USOklahoma City University · USUniversity of California, Irvine Medical Center · USUniversity of Cincinnati Medical Center · US

Funding

GYNECOLOGIC ONCOLOGY GROUP HEADQUARTERSU10CA027469 · GYNECOLOGIC ONCOLOGY GROUP · 1985 to 2005
$57.9M
GYNECOLOGIC ONCOLOGY GROUP STATISTICAL OFFICEU10CA037517 · ROSWELL PARK CANCER INSTITUTE CORP · 1985 to 2005
$29.0M
Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · 1994 to 2025
$19.5M
NRG Oncology Network Group Operations CenterU10CA180868 · NRG ONCOLOGY FOUNDATION, INC. · 2025 to 2025
$15.3M
Statistics CoreU10CA180822 · UNIVERSITY OF CHICAGO · 2025 to 2025
$10.2M
NRG Oncology Biospecimen BankU24CA196067 · NRG ONCOLOGY FOUNDATION, INC. · 2025 to 2025
$4.6M
INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDT32CA060396 · UNIVERSITY OF CALIFORNIA IRVINE · 1994 to 2005
$1.7M
Gynecologic Oncology Group- HUMAN SPECIMEN BANKU24CA114793 · GYNECOLOGIC ONCOLOGY GROUP · 2005 to 2005
$570k
NCI NIH HHS 1 U10CA180822NCI NIH HHS 2 T32 CA06039611NCI NIH HHS CA27469NCI NIH HHS CA37517NCI NIH HHS P30 CA062203NCI NIH HHS T32 CA060396NCI NIH HHS U10 CA027469NCI NIH HHS U10 CA037517NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180850NCI NIH HHS U10 CA180868NCI NIH HHS U10CA180868NCI NIH HHS U24 CA114793NCI NIH HHS U24 CA196067
6 · The paper itself

Abstract

objectiveThe aim of the study was to determine the differential expression patterns of the wingless-type (Wnt) pathway inhibitors Dkk3 (Dickkopf 3), SFRP1 (secreted frizzled-related protein 1), and SFRP4 in normal müllerian tissue and endometrial endometrioid adenocarcinoma specimens.

methodsMessenger RNA (mRNA) and protein levels of the Wnt pathway inhibitors Dkk3, SFRP1, and SFRP4 were evaluated by real-time reverse transcription-polymerase chain reaction and Western blot analysis. A total of 87 human tissue specimens were obtained from 60 women who participated in Gynecologic Oncology Group protocol 210. Twenty-seven normal müllerian tissues, 32 early-stage, and 28 advanced-stage endometrial endometrioid cancer specimens were analyzed.

resultsMedian age for this cohort was 60 years, with median body mass index of 32 kg/m. There was a difference in Dkk3 protein expression between normal müllerian tissues and primary endometrial endometrioid adenocarcinoma samples (P = 0.05). There was down-regulation of Dkk3, SFRP1, and SFRP4 mRNA expression in patients with high-grade disease (P = 0.08, 0.06, and 0.05, respectfully). Furthermore, a decrease in SFRP1 and SFPR4 mRNA expression was noted in patients with a diagnosis of locoregional and distant disease recurrence. Lastly, a trend toward decreased progression-free survival in patients with low Dkk3, SFRP1, and SFRP4 mRNA expression levels was noted.

conclusionsWnt pathway inhibitor (Dkk3, sFRP1, and/or sFRP4) expression was down-regulated in patients with high-grade disease and was associated with locoregional and distant disease recurrence. Despite sample size (power) limitations, these results support previous preclinical studies and may suggest a therapeutic role for Wnt signaling in endometrial cancer.

Indexed as

Adaptor Proteins, Signal TransducingAgedBiomarkers, TumorBlotting, WesternCarcinoma, EndometrioidChemokinesCohort StudiesEndometrial NeoplasmsFemaleFollow-Up StudiesHumansIntercellular Signaling Peptides and ProteinsMembrane ProteinsMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalAdaptor Proteins, Signal TransducingBiomarkers, TumorChemokinesDKK3 protein, humanIntercellular Signaling Peptides and ProteinsMembrane ProteinsProto-Oncogene ProteinsRNA, MessengerSecreted Frizzled-Related ProteinsSFRP1 protein, humanSFRP4 protein, human

Identifiers

PMID26397159
PMCPMC5061499
OpenAlexW2329032114

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.